Saturday 17 October 2026
Export LIMN’s income statement to Excel — free account
Liminatus Pharma Inc.
LIMN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 717.0%, free cash flow grew 89.0% and total debt was flat, each against the same quarter a year earlier.
3.04
0.17
−5.30%
Follow LIMN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 30.50 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 1,683.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 1 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | (4) | (10) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | — | (4) | (10) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | — | (10.13) | (21.50) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (4.15) | (20.97) | |||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | (0.03) | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (4.15) | (21.00) | |||||
| Book value | — | — | — | — | — | — | — | — | (55.26) | (20.66) | |||||
| Shares, m | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (1) | (10) | ||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (1) | (10) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | (19) | (10) | ||||
| Total debt | — | — | — | — | — | — | — | — | 20 | 1 | |||||
| Net debt | — | — | — | — | — | — | — | — | 20 | 1 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (19) | (10) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (344.72) | ||||
| ROIC | — | — | — | — | — | — | — | — | (360.95) | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 70.02 | |||||
Negative figures in brackets.
Charts ten years each
Liminatus Pharma Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DRMA Dermata Therapeutics, Inc. | $4.5M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ENLV Enlivex Ltd. | $4.5M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCNA NuCana PLC Sponsored ADR | $4.4M | — (loss-making) | — | — | n/m | +55.66% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| AZTR Azitra, Inc. | $4.3M | 1.0× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $4.3M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | |
| LNAI Lunai Bioworks Inc. | $4.2M | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| JUNS Jupiter Neurosciences, Inc. | $4.1M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | Compare |
| OSRH OSR Health, Inc. | $4.1M | — (loss-making) | — | −72.20% (below 0%: shrinking) | n/m | −398.76% (below 0%: shrinking) | 27.43% | (960.69%) | Compare |
| Median of peers | $4.4M | — | — | −72.20% | — | +4.17% | 25.60% | (480.34%) |
Liminatus Pharma Inc. (LIMN) key facts
- Liminatus Pharma Inc. (LIMN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, LIMN traded at $3.04, a market capitalization of $4.3 million.
- Return on equity was 70.0% and debt-to-equity 4.80.